



This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GlaxoSmithKline reaches settlement agreement with Biota

Issued –Monday 21 July 2008, London, UK

GlaxoSmithKline plc (GSK) today announced that it has reached a settlement in the litigation with Biota Holdings Limited regarding the commercialisation of *Relenza* (zanamivir). Under the terms of the settlement, GSK admits no liability but will make a payment of \$20million AUD (£10million) to Biota.

Andrew Witty, Chief Executive Officer of GlaxoSmithKline, commented, “We are pleased to have reached a settlement that is satisfactory for both companies and brings an end to this litigation. GSK remains committed to working collaboratively with external organisations and biotech companies, such as Biota, in our ongoing efforts to bring innovative medicines and vaccines to patients.”

This litigation was commenced by Biota in Australia in May 2004. The licensing agreement for *Relenza* is unaffected by the settlement.

Enquiries

UK Media enquiries:	Philip Thomson	(020) 8047 5502
	Claire Brough	(020) 8047 5502
	Alice Hunt	(020) 8047 5502
	Gwenan White	(020) 8047 5502
US Media enquiries:	Nancy Pekarek	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
	Sarah Alspach	(215) 751 7709
European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503
US Analyst/ Investor enquiries:	Frank Murdolo	(215) 751 7002
	Tom Curry	(215) 751 5419